Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial

Keyphrases

• Healthcare Resource Utilization 100%
• Meropenem 100%
• Nosocomial Pneumonia 100%
• Ceftolozane-tazobactam 100%
• Resource Utilization 66%
• Intention-to-treat 50%
• Mechanical Ventilation 33%
• Intensive Care Unit Length of Stay 33%
• Extubation 33%
• Utilization Outcomes 33%
• Treatment Group 16%
• Confidence Interval 16%
• Randomized Double-blind 16%
• Clinical Trials 16%
• Trial Registration 16%
• Length of Stay 16%
• Length of Hospital Stay 16%
• Ventilator-associated Pneumonia 16%
• Mortality Rate 16%
• Hospital Discharge 16%
• Intensive Care Unit 16%
• Pseudomonas Aeruginosa (P. aeruginosa) 16%
• Intensive Care Unit Discharge 16%
• Resource Use 16%
• Gram-negative Pathogens 16%
• Real-world Practice 16%
• Non-inferiority 16%
• Practice Setting 16%
• Ventilation Rate 16%
• P. Aeruginosa Infection 16%
• Hospital-acquired 16%
• EudraCT 16%
• Hospitalization Days 16%
• Tazobactam 16%
• Ceftolozane 16%
• Numerical Difference 16%

Medicine and Dentistry

• Meropenem 100%
• Tazobactam 100%
• Ceftolozane 100%
• Intensive Care Unit 57%
• Artificial Respiration 42%
• Intention-to-Treat Analysis 42%
• Pseudomonas aeruginosa 28%
• Extubation 28%
• Infection 14%
• Clinical Trial 14%
• Mortality Rate 14%
• Pathogen 14%
• Bacterial Pneumonia 14%
• Treatment Group 14%

Agricultural and Biological Sciences

• Tazobactam 100%
• Pseudomonas aeruginosa 28%
• Confidence Interval 14%